United Therapeutics Corporation

• UTHR Stock Price 24h change: -0.79%. From 475.59 USD to 471.99 USD. (Note: As of Jan 16, 2026, the stock has faced downward pressure, declining roughly 5% year-to-date as the market digests recent multi-year gains and reacts to significant insider selling activities totaling over $280 million in the past 90 days.)
• From a technical perspective, UTHR is currently in a "short-term bearish correction" within a long-term bullish frame. The stock is trading below its 5-day (465.00) and 20-day (470.90) EMAs, with the RSI at 27.9 indicating an oversold condition. Support is seen near $461.47, while immediate resistance sits at $478.51 (50-day EMA).
• United Therapeutics CEO Dr. Martine Rothblatt presented a company update at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, highlighting the firm's mission as a Public Benefit Corporation and progress in organ transplant technologies.
• SEC filings revealed that COO Michael Benkowitz sold 22,500 shares on January 12 at an average price of $479.51, part of a broader trend of executive divestment that has caught investor attention despite strong fundamental net margins of 40.65%.
• UBS Group recently maintained a "Buy" rating on UTHR, raising its price objective from $600 to $645, citing long-term growth potential in pulmonary arterial hypertension (PAH) therapies regardless of short-term volatility.
• Analysts at the J.P. Morgan Healthcare Conference (Jan 12-16) noted that while the biotech sector IPO market remains quiet, a significant rebound is expected for 2026 driven by lower interest rates and mature clinical trial data in oncology and respiratory disease.
• The broader biotech industry saw a surge in M&A speculation during mid-January 2026, with major players like Eli Lilly and Merck reportedly eyeing mid-cap targets, providing a sentiment floor for specialized drug manufacturers despite a slow start to the year.

• UTHR Stock Price 24h change: -0.79%. From 475.73 USD to 471.99 USD. (Jan 15, 2026 close)
• The price decrease followed news of executive insider selling, with EVP Paul Mahon liquidating approximately $3.9 million worth of shares, despite a recent price target hike to $645 by UBS.
• From a technical perspective, the stock is showing "short-term weakness within a long-term bull trend": UTHR is currently trading below its 20-day and 50-day moving averages, with a bearish MACD and a neutral-to-low RSI of 38, suggesting a consolidation phase near the bottom of its recent monthly range.
• United Therapeutics EVP Paul Mahon sold 8,300 shares on January 15 at an average price of $469.89, reducing his direct ownership by approximately 18%.
• The company presented at the 44th Annual J.P. Morgan Healthcare Conference on January 12, highlighting its rare disease pipeline and progress in xenotransplantation clinical trials.
• United Therapeutics' Phase 3 Ralinepag trial reached completion recently, setting up a key potential catalyst for its pulmonary arterial hypertension (PAH) franchise.
• The biopharma sector showed renewed optimism at the J.P. Morgan Healthcare Conference, with analysts predicting a surge in M&A activity and a "Sputnik moment" for US biotech innovation in 2026.
• ImmunityBio shares surged over 30% this week following positive CAR-NK cell therapy data, highlighting strong investor appetite for breakthrough oncology and cell therapy results.